- VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”).
- Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites.
- The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute.
- VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb.
- The company reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, alongside additional pending applications.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element of its approach.
At a glance
- Company
- VERAXA Biotech
- Ticker
- NASDAQ: VRXA
- Announcement
- Product
Key figures
- Granted owned or exclusively licensed patents
- more than 50
- Patent families
- 26
- Countries with patent coverage
- 14
Products and programs
The latest pipeline development involves VXA-222, a bispecific antibody-drug conjugate that has moved beyond the initial discovery phase following the completion of VERAXA’s collaboration with OmniAb. VERAXA is now responsible for engineering the final therapeutic candidate using antibody binders generated through the collaboration, followed by…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What is a bispecific antibody-drug conjugate?
A bispecific antibody-drug conjugate combines an antibody designed to bind two different targets with a drug attached to the antibody. The binding features can help direct the conjugate toward cells bearing relevant targets, while the attached drug is intended to deliver a therapeutic effect. The design and behavior vary by candidate.
How does an AND-gated antibody approach work?
An AND-gated approach is designed to produce an effect when multiple intended recognition conditions are met, rather than responding to just one signal. In cancer therapy, this can be used to seek greater selectivity for tumor sites. VERAXA says its BiTAC platform uses this type of dual-targeting architecture to favor activity at tumor sites.
What is the development status of VERAXA's VXA-222 program?
The release says VXA-222, a bispecific antibody-drug conjugate, has moved beyond the initial discovery phase after completion of the antibody-discovery step in a collaboration with OmniAb. VERAXA says it is responsible for engineering the final therapeutic candidate using the antibody binders generated through that collaboration.
What does IND/CTA-enabling development mean?
IND/CTA-enabling work consists of studies and preparations intended to support an application to begin clinical testing. IND refers to an Investigational New Drug application in the United States; CTA refers to a Clinical Trial Application used in other regulatory systems. The release says VERAXA's lead BiTAC-TCE has advanced toward this stage after cell-line development work and regulatory feedback from Germany's Paul-Ehrlich-Institute.
SEC filings
- 4FORM 4 Filed
- 4FORM 4 Filed
- 6-KReport of a foreign issuer Filed
- 3FORM 3 Filed
- SCHEDULE 13G/ASCHEDULE 13G/A Filed
- 424B5Prospectus supplement Filed
- 424B5Prospectus supplement Filed
- EFFECTEFFECT Filed
- EFFECTEFFECT Filed
- F-1/AF-1/A Filed
- F-1/AF-1/A Filed
- F-1F-1 Filed
- F-1F-1 Filed
- 6-KReport of a foreign issuer Filed
- 6-KReport of a foreign issuer Filed
Earlier from VERAXA Biotech
- VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
- VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
- VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
- VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
- VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
